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PRESCRIPTION DRUGS AND DISCOUNTS: THE PHARMACIST'S VIEW  
Said Q1, Hood KM2, Heldenbrand SD1 
1University of Arkansas for Medical Sciences, Little Rock, AR, USA, 2University of Arkansas at 
Little Rock, Little Rock, AR, USA  
OBJECTIVES: Pharmaceutical companies have designed prescription drug 
coupons and copay cards (CCCs) programs to maintain brand name medication 
loyalty, especially for medications that have just, or are about to lose their 
patent. The objective of this study is to evaluate perceptions of retail 
pharmacists about coupon and copay card (CCC) programs. METHODS: 
Pharmacists in the state of Arkansas, USA, were surveyed online. Questions on 
5-point likert scale focused on pharmacist’s perceptions towards CCC's regarding 
benefits to patients, public health, medication compliance, pharmacist workload, 
as well as barriers to pharmacy practice. Chi-square and multivariate logistic 
models were used to analyze the data. RESULTS: Of the approximately 1200 
subjects 325 took the survey. Excluding missing values, 214 subjects were 
included in final analysis. Of these, 56% were male, 47% were less than 35 years 
of age, and 46% worked in a franchise or chain pharmacy, 40% were located in 
urban or suburban areas, 60% were in semi-urban or rural areas. Regression 
results indicated that full-time pharmacist practicing in larger pharmacies and 
processing higher numbers of CCCs had more favorable views towards patient 
satisfaction with CCCs (all p-values<0.05). Most pharmacists were reluctant to 
express that CCCs saved patients money, were good for public health, or 
improved medication compliance. Most pharmacists agreed that CCCs increased 
pharmacy workload, however highly satisfied pharmacist with proper staffing 
disagreed. Female pharmacists were more likely to explain CCC use to patients. 
Pharmacists working in high-volume chain and urban environments were least 
likely to state difficulties processing CCC transactions. All p-values in regression 
results reported above were <0.05 with odds ratios ranging from 1.05 to 2.5 (note: 
individual p-values and odds ratios are too many to report because of word 
limit). CONCLUSIONS: With increasing prevalence of CCCs, this study provides 
key insights into perceptions of pharmacists.  
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THE ROLE OF HEALTH SHOCKS IN LATE PART D ENROLLMENT  
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1PhRMA, Washington DC, DC, USA, 2AHRQ, Rockville, MD, USA, 3University of Maryland School 
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OBJECTIVES: Enrollment in Medicare Part D is voluntary; however, mechanisms 
exist to encourage early enrollment and improve risk pooling, including a 
permanent premium penalty associated with delayed enrollment and restricted 
enrollment periods. This study examined whether a health shock would create 
adequate incentives to overcome the penalties associated with late enrollment. 
METHODS: Using enrollment and claims from a random 5% sample of Medicare 
beneficiaries from 2006 to 2008, we observed Part D enrollment decisions among 
beneficiaries who had failed to enroll in Part D at first eligibility (N=207,674). A 
health shock was defined as a hospital admission due to a drug-intensive 
chronic condition. Multivariable logistic regression examined the impact of a 
health shock on the probability of late Part D enrollment, controlling for 
beneficiary demographics, pre-existing chronic conditions, preventive service 
use, and admission to a facility. We also examined whether timing of the 
hospitalization relative to the next available enrollment period influenced the 
likelihood of Part D enrollment. RESULTS: Eighteen percent of beneficiaries in 
the cohort enrolled late into Part D. Initial and subsequent hospitalizations for 
drug-intensive conditions were associated with 5 and 7 percentage point 
increases in the probability of Part D enrollment, respectively (p<0.01). A gap 
from the time of hospitalization to the next coverage period was associated with 
a lower likelihood of enrollment among non-Low Income Subsidy (LIS) 
recipients, but had no relationship for LIS enrollment, which is not restricted to 
enrollment periods. CONCLUSIONS: Health shocks were associated with an 
increased likelihood of late Part D enrollment, but many beneficiaries remained 
without Part D coverage despite deterioration in their health status and expected 
increased need for drugs. Non-enrollees were forced to either absorb the full cost 
of medications or forgo them, which can have negative effects on health and, the 
potential to increase Parts A and B spending.  
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EFFECT OF PLACEMENT OF WARNING INFORMATION ON OTC DRUG FACTS 
PANEL: IMPROVING EASE OF USE AND PURCHASE INTENTION  
Bhansali AH, Sangani DN, Mhatre S, Sansgiry SS 
University of Houston, Houston, TX, USA  
OBJECTIVES: Order in which warning information is presented on the over-the-
counter medication Drug Facts panel could enhance patient safety. This study 
assessed the effect of placement of warning information on OTC Drug Facts 
panel to provide guidance to the FDA in enhancing appropriate product use. 
METHODS: Two experimental labels (current and new) were developed from an 
existing marketed drug product by varying the sequence of information to- uses, 
directions, other information and warnings (new) vs uses, warnings, directions 
and other information (current). In this repeated measure experimental study, 
each participant evaluated labels on ease of use and purchase intention using an 
eleven point scale with appropriate scale anchors. The order in which 
participants viewed the label was randomized. Mean score for ease of use and 
purchase intention was contrasted between labels using match paired t-test. 
RESULTS: Of the 297 study participants (71% response rate), majority were males 
(60.4%) with a mean (±SD) age of 21.3 (±1.8) years. More than half (55%) indicating 
they often read labels, while 70% were currently not on any medications. The 
mean (±SD) scores were significantly (p<0.0001) higher for ease of use for the 
new (8.0±1.2) as compared to the current label design (6.8±1.2). Similarly the 
mean purchase intention were also significantly (p<0.0003) higher for the new 
label design (7.8±1.4) compared to current label (7.4±1.2). CONCLUSIONS: The 
prototype new label developed with congruent information where uses and 
directions were clustered and were followed by warnings was perceived better. 
This information can help guide the FDA to conduct more studies and develop 
policy changes as necessary to improve information comprehension from OTC 
Drug Facts panel.  
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PERCEPTIONS AND BARRIERS TO PARTICIPATION IN CLINICAL RESEARCH OF 
PRIMARY CARE PHYSICIANS  
Atzinger CB, Siebenaler J 
OptumInsight, Eden Prairie, MN, USA  
BACKGROUND: The number of physicians willing to participate in clinical 
research has been on the decline in the US and Europe for the last decade. This 
trend is contrary to projected research needs as a result of expanded regulatory 
requirements for post-marketing studies of new drugs and devices and the need 
for more comparative effectiveness data. The problem is further magnified when 
considering the need for research data from the front lines of primary medical 
care, where the majority of patients receive their initial and ongoing care. 
OBJECTIVES: The primary objective of this study is to assess primary care 
physician (PCP) perceptions toward practice-based clinical research and identify 
barriers they face when deciding to participate in projects. METHODS: A web-
based survey was distributed to over 4000 PCPs over a 30-day period. 
Respondents were asked about demographics, practice type, practice size, and 
prior clinical research experience. Respondents were divided into two cohorts 
based on prior research experience. Respondents were asked to evaluate the 
value of clinical research and barriers to participation. RESULTS: Survey 
responses were received from 109 PCPs, who were divided into two cohorts 
based on overall research experience. The cohorts were well matched for age, 
gender, specialty, practice size, and patient volume. Approximately 40% of sites 
with minimal research experience responded negatively to the value of clinical 
research, its impact on patient care or benefit to patients. Over 50% reported that 
and that their patients would not be interested in participation in research, 
regardless of study design, nor would they be willing to refer patients to 
physicians conducting research in which they patient could benefit. 
CONCLUSIONS: Sponsors must work more diligently to demonstrate the value of 
practice-based research and create incentives in order to recruit community-
based physicians for clinical research studies.  
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IN TREATMENT WITH BUPRENORPHINE  
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OBJECTIVES: HCV infection rates have been gradually increasing for the past 10 
years in the US with drug injection being reported as a primary cause. 
Buprenorphine, with its unique pharmacological profile is a common form of 
treatment for opioid dependence. The aim of this analysis was to determine 
whether opioid-dependent patients infected with HCV and being treated with 
buprenorphine are less likely to achieve the same levels of opioid abstinence as 
those who are not infected. METHODS: The data for this investigation came from 
the National Drug Abuse Treatment Clinical Trial Network study 0003, where, 
after buprenorphine stabilization, the effects of a 7 versus a 28 day tapering 
schedule was compared . Missed urinalyses were coded as positive for opioids. 
Binary logistic regression models were used to test the likelihood of providing an 
opioid-positive urine at baseline (immediately following stabilization), and at the 
end of the treatment period. An ordered logistic regression model tested the 
presence of HCV on the total number of positive urine tests submitted during the 
treatment period. RESULTS: A total of 35.73%of the participants in the overall 
sample tested positive for the HCV antibody. At baseline, there was a 60% 
increase in the odds of HCV patients testing positive/missing for opioid use, 
relative to non-HCV participants. there was a significant effect of HCV status on 
the total number of opioid positive urines submitted during the treatment 
period. However, HCV status was not significantly associated with the likelihood 
of a positive/missing urinalysis at the end of the treatment period. 
CONCLUSIONS: Individuals infected with HCV are less likely to provide opioid-
free urine samples while being treated for opioid dependence with 
buprenorphine. This is an important, albeit exploratory finding that could 
significantly aid in developing future treatment strategies in managing HCV-
infected opioid-dependent patients.  
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OBJECTIVES: Most accounts put the research and development cost of bringing a 
new drug to market close to $1B USD (Adams and Brantner, 2010; Dimasi, et al., 
2003). At this price, manufacturers cannot afford to launch a product that fails to 
meet market expectations, yet often products do not perform as anticipated. 
This effort looks at high-profile FDA approvals and evaluates the market 
performance with particular emphasis on exploring the reasons drugs do not 
meet the predicted revenue targets in the first year of sales. METHODS: We 
examined the 2010 and 2011 drug approvals to select the most appropriate NME 
to examine. Using data from EvaluatePharma®, we compared the forecasted 
annual sales estimate just prior to launch with the actual annual sales in the 
first year on the market. For the products that failed to meet expectations we 
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examined the news reports from online journals, websites, and reputable news 
outlets to determine the most likely reason for drug failure. RESULTS: Of 31 
products included in the analysis 16 failed to meet the expectations announced 
in the month prior to launch. We attributed price or reimbursement as the 
reason that seven of the 16 products failed to meet market expectations. 
Competition due to existing product dominance, near-simultaneous launches for 
the same patient population, and widely available generics explained the failure 
of five products. Efficacy questions and label restrictions contributed to the slow 
uptake of three products. Capacity can be faulted on another product. 
CONCLUSIONS: As the landscape changes, manufacturers must consider 
product differentiation and market assessment early to anticipate the market’s 
price threshold to avoid a key pitfall in new product launches.  
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ANALYZING INVESTOR PREFERENCE TOWARDS BIO-TECHNOLOGY COMPANIES 
IN DIFFERENT PHASES  
Furnback W, Magyar AF, Wang B 
Alliance Life Sciences, Somerset, NJ, USA  
OBJECTIVES: While many small biotechs are acquired by larger pharmaceuticals, 
few attempt a full scale commercialization of their product. We analyzed the 
stock market returns of three small, single drug bio-technology firms which had 
drugs approved by the FDA in 2010. METHODS: The historical prices adjusted for 
corporate action were used for all three firms from Q4 2007 through Q3 2012 
which accounted for 1,261 trading days per company. All products have been 
approved by the FDA for at least 8 quarters. Each company’s prices were broken 
up into daily and quarterly intervals as well as pre-launch and post-launch. 
Simple statistics and t-tests were run on the stock returns for all intervals. 
RESULTS: On average, the pooled total return associated with the pre-launch 
phase was 212.6% higher than post-launch. The average pooled quarterly and 
daily returns during the pre-launch period were 19.1% and .37% higher than the 
post-launch period, respectively. The standard deviation of the daily returns 
during the pre-launch period was on average 24% higher than during the post-
launch period. A two-tail t-test assuming unequal variances was run on each of 
the daily stock prices with a hypothesized mean difference of 0 between pre-
launch and post-launch, for all three of the companies the p-value was <0.05. 
CONCLUSIONS: Investors seemed to prefer the pre-launch period which received 
a greater return on investment. The difference in the mean prices for each 
company in the different phases was statistically significant. However this 
analysis is relatively early in the post-launch term for each drug as smaller 
companies tend to gain market share more slowly than larger pharmaceuticals. 
The stock returns of these companies seem to be highest in the pre-launch 
phase as opposed to post-launch.  
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OBJECTIVES: To describe the trends in published comparative cost analyses from 
2010 through 2012 for interventions in cancer (CA), diabetes (DM), and 
cardiovascular diseases (CVD). METHODS: A PubMed search of articles published 
between January 2010 and December 2012 was conducted utilizing the following 
search strategy/terms: (cost-effectiveness OR cost-utility OR cost-benefit) AND 
(cancer OR diabetes OR cardiovascular diseases). Articles were excluded if they: 
1) did not contain sufficient information to determine the type of analysis 
conducted; 2) focused on a sequelae of a treatment; 3) no comparative analysis 
was conducted; 4) only costs were considered; or 5) were reviews, editorials, or 
commentaries. The abstracts of the articles, not the full articles themselves, 
were evaluated and used to classify comparative economic analyses by disease 
focus, intervention type, intervention target (e.g., treatment, prevention), 
economic analysis performed, geographic region of population/perspective of the 
analysis, and primary/corresponding author affiliations. Descriptive statistics 
were conducted in PASW Statistics 18.0. RESULTS: The initial search yielded 
3,868 abstracts. Of these, 725 studies were retained in the final analysis (254 in 
2010, 226 in 2011, 245 in 2012). In 2010, 2011 and 2012, respectively, 134, 119, 150 
studies were in CA, 25, 23, 35 in DM, and 95, 84, 60 in CVD. Approximately 63.7% 
of studies across years focused on active treatment or secondary prevention. A 
pharmaceutical, vaccine, or lifestyle intervention was the focus in 47.9% of 
studies. A majority (70.2%) of the studies utilized cost-utility analyses, which was 
consistent across all years, with most study populations/study perspective in 
European countries. CONCLUSIONS: Comparative economic analyses from 2010-
2012 had a heavy focus on active or secondary interventions in CA and in 
European populations. As value-based pricing and health care reform emerges, 
more extensive utilization and publication of comparative cost effectiveness 
analyses will be required.  
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THE HEALTH AND ECONOMICS BULLETIN – AN ANALYSIS OF FOUR YEARS OF 
PUBLICATION  
Lima SO, Calais GSP, Caldeira TR, Garcia GC, Gava CM, Troncoso GCBCEC 
Brazilian Health Surveillance Agency (Anvisa), Brasília, Brazil  
OBJECTIVES: The Health and Economics Bulletin is an electronic periodic of The 
Brazilian Health Surveillance Agency (ANVISA). It aims to provide information to 
health care decision-makers and patients when there is more than one 
pharmaceutical option to treat the same disease and there is no scientific 
evidence of superiority in terms of safety and efficacy among drugs. This bulletin 
intends to improve health care efficiency when it points out the differences on 
treatment costs among the drugs. The objective of this study is to analyze all 
editions of The Health and Economics Bulletin available on ANVISA website. 
METHODS: Data were collected from editions of Health and Economics Bulletin 
published since August 2009 (month of launch) until September 2012. The 
variables considered were: number and type of diseases, therapeutic classes, 
active substance, drugs and treatment costs. RESULTS: Eight editions of the 
bulletin were published and each number addressed a different disease such as 
osteoporosis, glaucoma, gastroesophageal reflux, arterial hypertension, epilepsy, 
dyslipidemia, erectile dysfunction and allergic rhinitis. In total, 12 therapeutic 
classes were evaluated which comprises biphosphonates and oral 
antihistamines on osteoporoses and allergic rhinitis editions, respectively. A 
total of 33 active substances and 64 drugs were assessed, including generics, 
similars and brand drugs. Sixty four costs of treatment were performed which 
demonstrated considerable differences between drugs prescribed for the same 
disease. For example, on the allergic rhinitis edition, it was found 231% of 
difference on treatment costs between the most expensive and the lowest cost 
drugs although they have similar safety and efficacy levels, based on scientific 
evidences. CONCLUSIONS: The Health and Economics Bulletin is an important 
information tool and was elaborated to improve the critical view of health care 
decision-makers and patients. Considering differences of treatment costs among 
drugs that have the same safety and efficacy, they can select the drugs more 
efficiently.  
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ON THE WORKFLOW OF THE INPATIENT HOSPITAL ORDER ENTRY 
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OBJECTIVES: The amount of time spent in different activities by inpatient order 
entry pharmacists in a computerized provider order entry (CPOE) versus a non-
CPOE setting. METHODS: A prospective, pretest-posttest, time and motion study 
design was used to compare the workflow of order entry pharmacists in an 
inpatient hospital setting. Randomized data collection was conducted at two 
time periods in the same hospital: the pretest period was immediately before 
implementation of the CPOE system and the posttest period was 5.5 months 
post-implementation. A pre-validated data recording instrument was used to 
record 37 different pharmacist tasks, which were grouped into four activities: 
clinical, distributive, administrative, and miscellaneous. Comparisons of the 
amount of time spent by the order entry pharmacist per hour in each of the four 
different activities were conducted. SAS® version 9.3 was used to analyze the 
data, with statistical significance set at 0.05. RESULTS: A total of 37 hours were 
collected pre-intervention, and 42 hours post-intervention. The amount of time 
(mean number of minutes per hour±SD pre-intervention versus post-
intervention, p-value) for the activities were: clinical (2.0±3.8 vs. 1.9±2.6, p=0.89); 
distributive (45.2±11.3 vs. 49.3±8.1, p=0.11); administrative (10.6±9.8 vs. 6.0±6.5, 
p<0.05); and miscellaneous (2.1±3.2 vs. 2.8± 4.0, p=0.64). CONCLUSIONS: Less time 
was spent by order entry pharmacists in the administrative activity after the 
implementation of CPOE, which translates to more pharmacist time spent in 
other activities. Management should to be aware of the implications of CPOE 
implementation on pharmacist workflow.  
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EXPLORING DIFFERENCES ACROSS THE INDEPENDENT ACADEMIC CENTRES IN 
THE OUTCOMES OF THE NICE APPRAISAL PROCESS  
Macaulay R 
HERON Health, Luton, UK  
OBJECTIVES: When developing technology appraisals guidance, NICE (National 
Institute for Health and Clinical Excellence) commissions an independent 
academic centre to critically appraise the manufacturer's submission and 
prepare an Evidence Review Group (ERG) report that reviews the published 
evidence on the relevant technology. NICE has used 11 different academic 
centres to support the work of appraisal committees in the Single Technology 
Appraisal (STA) process and this research aimed to explore whether there were 
differences in acceptance rates between these centres. METHODS: All final 
appraisal determinations (FADs) resulting from STA processes were identified 
(August 2006 – December 2012) from which the recommendation and the 
appraising academic centre were extracted. Acceptance rates were compared 
across the 8 academic centres that made at least 5 recommendations using a Chi 
squared test. RESULTS: This research considered 94 submissions, from which 
106 recommendations were generated. The number of acceptances or rejections 
was not found to differ significantly by centre (p=0.810). Of these centres, the 
highest proportion of NICE positive recommendations followed ERG appraisals 
by Southampton (86%) and the lowest proportion by Liverpool (61%). In between 
were Peninsula (78%), York (77%), Sheffield (76%), Aberdeen (67%), Kleijnen (67%), 
and Birmingham (62%). Nevertheless, the considered therapy areas substantially 
varied between different academic centres, with certain therapy areas being 
preferentially or even exclusively appraised by specific centres. Oncology was 
the most commonly-appraised area overall (47% of recommendations) and the 
appraisal of oncology submissions was not evenly distributed between the 
different academic centres (P<0.001). There were no significant variations in the 
distribution of orphan drugs assessed or in the proportion of restricted 
recommendations issued. CONCLUSIONS: Despite large variations in therapy 
areas considered, the likelihood of a positive recommendation does not appear 
